Carcinoid Tumor Clinical Trial
Official title:
A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04993261 -
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
|
Early Phase 1 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Active, not recruiting |
NCT03375320 -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 3 | |
Completed |
NCT01435122 -
A Study of Axitinib in Advanced Carcinoid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04039516 -
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
|
Phase 2 | |
Completed |
NCT00780663 -
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
|
Phase 2 | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Completed |
NCT03723499 -
Endoscopic Treatment of Bronchial Carcinoid Tumors
|
||
Recruiting |
NCT04017104 -
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
|
||
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Completed |
NCT00328497 -
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
|
Phase 2 | |
Completed |
NCT02399215 -
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT03420521 -
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT05477576 -
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
|
Phase 3 | |
Not yet recruiting |
NCT02038738 -
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00446082 -
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
|
Phase 1 | |
Active, not recruiting |
NCT05361668 -
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
|
Phase 2 | |
Completed |
NCT01466036 -
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 2 |